A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

53 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-01

Study Completion Date

2016-11-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

For patients with non-resectable cholangiocarcinoma, gemcitabine with cisplatin is considered as the reference treatment in first line chemotherapy. However, the outcomes of these patients remain limited and therefore more effective drugs are warranted. The context of the disease and current data on sunitinib suggest that sunitinib may have activity in patients with advanced non resectable cholangiocarcinoma.

Thereby, it is proposed to conduct an open label single arm trial aiming evidencing activity of sunitinib in such a patient population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors

NCT01731925

Carcinoid Tumors

UNKNOWN PHASE2

Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line

NCT02187042

Metastatic/Advanced Renal Cell Carcinoma

COMPLETED

Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma

NCT02689167

Kidney Neoplasms Metastatic Renal Cell Cancer

UNKNOWN PHASE2

Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma

NCT01082809

Advanced Biliary Tract Adenocarcinoma

COMPLETED PHASE2

Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma

NCT01215565

Hepatocellular Carcinoma Fibrolamellar Hepatocellular Carcinoma

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective is to evaluate the overall survival of patients with advanced and unresectable cholangiocarcinoma treated continuously by sunitinib as second line at the dose of 37.5 mg per day, after one line of chemotherapy and to determine whether sunitinib deserves further studies in this indication.

The secondary objectives are

* To evaluate the criteria of efficacy
* To evaluate the effects of sunitinib on tumor angiogenesis
* To characterize the safety profile of sunitinib
* To identify markers associated with response to sunitinib

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Unresectable and Advanced Cholangiocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

open label, single arm

single arm: sunitinib until progresion or unacceptable toxicity

Group Type EXPERIMENTAL

Sunitinib

Intervention Type DRUG

sunitinib dose :37.5mg/day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sunitinib

sunitinib dose :37.5mg/day

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

sutent

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Written informed consent given according to ICH/GCP, and local regulation.
2. Histologically or cytologically proven intrahepatic cholangiocarcinoma.
3. Disease that is not amenable to surgery, radiation, or combined modality therapy with curative intent.
4. Gemcitabine with or without platinum pre-treated patients with documented progression
5. Local, locally-advanced or metastatic disease documented as having shown progression on a scan (CT, MRI).
6. Measurable tumor according to RECIST criteria with at least one unidimensionally measurable target lesion
7. No evidence of biliary duct obstruction unless obstruction controlled by local treatment or, in whom the biliary tree can be decompressed by endoscopic or percutaneous stenting with subsequent reduction in bilirubin £ 1.5xULN.
8. Age between 18 and 80 years old
9. Eastern Cooperative Oncology Group (ECOG) Performance Status :0-1
10. Life expectancy ≥ 3 months.
11. Ability to swallow oral compound.
12. No acute toxic effects of previous treatment superior to grade to 1.
13. Laboratory requirements:

Hematologic: absolute neutrophil count (ANC) 1.5 x 103/mm3, platelets 100 x 103/mm3, hemoglobin 9 g/dl and Hepatic: Bilirubin \< 1.5 x upper normal limit (ULN), and alkaline phosphatase (AP) 5xULN. AST and ALT may be 5 x ULN Patients with jaundice Prothrombin time and partial thromboplastin time 1.7 xULN, serum albumin 2.8 g/dl. Renal: Serum creatinine 1.5 xULN , and clearance \> 60 ml/min.
14. Normal cardiovascular function
15. Adequate organ function
16. No cardiovascular events during the year prior to study entry
17. Female patients must be surgically sterile or postmenopausal, or must agree to use effective contraception during the period of therapy. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) within 7 days prior to starting study drug. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the investigator or a designated associate
18. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
19. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures
20. Registration in a national health care system (CMU included).

Exclusion Criteria

1. Hilar cholangiocarcinomas, cholangiocarcinomas located in the gall bladder, hepatic capsule effraction, extrahepatic primary cholangiocarcinoma, carcinoma of the Water ampullum.
2. Prior treatment with other chemotherapy than gemcitabine and/or platinum.
3. Concomitant treatment with any chemotherapy, chemoembolization therapy, immunotherapy, antitumoral hormonotherapy or investigational anticancer agents..
4. Prior treatment with any tyrosine kinase inhibitors or anti-VEGF angiogenic inhibitors.
5. Diagnosis of any second malignancy within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri.
6. Treatment with potent CYP3A4 inhibitors and inducers within 7 and 12 days, respectively prior to study drug administration.
7. Pre-existing thyroid abnormality of thyroid function that cannot be maintained in the normal range with medication.
8. Concomitant treatment with therapeutic doses of anticoagulants (low dose warfarin (Coumadin) up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed).
9. Unstable systemic diseases including uncontrolled hypertension (\>150/100 mmHg despite optimal medical therapy) or active uncontrolled infections.
10. Drug having proarrhythmic potential (terfenadine, quinidine,procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone, indapamide and flecainide).
11. Any of the following within the 12 months prior to study drug administration: myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism.
12. Abnormal cardiac function with abnormal 12 lead ECG. Ongoing cardiac dysrhythmias of NCI CTC grade2, atrial fibrillation of any grade, or prolongation of the QTc interval to \>450 msec for males or \>470 msec for females.
13. Symptomatic brain metastases, spinal cord compression, or new evidence of brain or leptomeningeal disease.
14. Current treatment with any other investigational medicinal product.
15. Positive test for human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness
16. Pregnancy or breastfeeding.
17. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No